Title: Rolf Larsson: Innovator in Cancer Treatment
Introduction
Rolf Larsson is a notable inventor based in Sweden, recognized for his contributions to cancer treatment innovations. With a focus on developing novel therapeutic approaches, he has made significant strides in the field of oncology.
Latest Patents
Rolf Larsson holds a patent for a method involving the treatment of solid tumors. This method utilizes a cell-permeable iron chelator, which can be combined with an autophagy-inhibiting agent for enhanced efficacy. A preferred chelator in this patent is an alkyl-substituted N-(1-pyridine-2-yl-methylidene)-N-(9H-1,3,4,9-tetraaza-fluoren-2-yl)-hydrazine, while chloroquine is identified as a preferred autophagy-inhibiting agent. The patent also describes a pharmaceutical composition that includes the iron chelator and a pharmaceutically acceptable carrier, aimed at treating cancer effectively.
Another significant patent by Larsson involves azepanone compounds that inhibit deubiquitinating activity, which can be particularly useful in treating cancers that are resistant to conventional chemotherapy. This patent outlines the structure of the compound and its potential applications in cancer treatment, along with corresponding methods and pharmaceutical compositions.
Career Highlights
Throughout his career, Rolf Larsson has worked with several companies, including Corline Systems AB and Oncopeptides AB. His work in these organizations has contributed to the advancement of cancer therapies and the development of innovative treatment methods.
Collaborations
Rolf Larsson has collaborated with notable professionals in the field, including Rolf Lewensohn and Joakim Gullbo. These collaborations have fostered a productive environment for research and development in cancer treatment.
Conclusion
Rolf Larsson's innovative work in cancer treatment showcases his commitment to improving therapeutic options for patients. His patents reflect a deep understanding of the complexities of cancer and a dedication to finding effective solutions.